Oncopharmpod
Acalabrutinb + BR and sotorasib + panitumumab
- Author: Vários
- Narrator: Vários
- Publisher: Podcast
- Duration: 0:08:47
- More information
Informações:
Synopsis
FDA approves two new treatment regimens: 1. Acalabrutinib + BR for untreated mantle cell lymphoma patients deemed ineligible for autologous HSCT 2. Sotorasib + panitumumab for KRAS-G12C mutated metastatic colorectal cancer (after chemotherapy, including oxaliplatin and irinotecan)
